ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements for the Nine Months Ended December 31, 2013 ALKERMES PLC Table of Contents

Total Page:16

File Type:pdf, Size:1020Kb

ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements for the Nine Months Ended December 31, 2013 ALKERMES PLC Table of Contents ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Nine Months Ended December 31, 2013 ALKERMES PLC Table of Contents Directors’ Report ........................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ............................................ 59 Consolidated Statement of Comprehensive Income .................................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 62 Consolidated Reconciliation of Shareholders’ Funds .................................. 63 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 105 Company Balance Sheet ...................................................... 107 Notes to the Company Financial Statements ....................................... 108 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the nine months ended December 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2013, which provides that a true and fair view of the state of affairs and profit or loss may be given by preparing the financial statements in accordance with accounting principles generally accepted in the United States of America (‘‘U.S.’’) (‘‘GAAP’’), as defined in Section 1(1) of the Companies (Miscellaneous Provisions) Act 2013, to the extent that the use of those principles in the preparation of the financial statements does not contravene any provision of the Companies Acts or of any regulations made thereunder. On May 21, 2013, our Audit and Risk Committee, with such authority delegated to it by our Board of Directors, approved a change to our fiscal year-end from March 31 to December 31. This Directors’ Report covers the nine-month transition period ended December 31, 2013 and reflects our financial results for the nine-month period from April 1, 2013 through December 31, 2013(the ‘‘Transition Period’’). The prior period presented in this Directors’ Report covers the fiscal year ended March 31, 2013 and reflects financial results for the twelve-month period from April 1, 2012 to March 31, 2013. NOTE REGARDING TRADEMARKS CODAS↧, IPDAS↧, LinkeRx↧, MXDAS↧, NanoCrystal↧, SODAS↧, VERELAN and VIVITROL↧ are registered trademarks of Alkermes. The following are trademarks of the respective companies listed: ABILIFY and ABILIFY MAINTENA↧—Otsuka Pharmaceutical Co., Ltd.; ADALAT↧— Bayer AG Corporation; AFEDITAB↧—Actavis, Inc.; AMPYRA↧, FAMPYRA↧, ZANAFLEX and ZANAFLEX CAPSULES↧—Acorda Therapeutics, Inc.; ANTABUSE↧—Teva Women’s Health, Inc.; AUBAGIO↧—Sanofi Societe Anonyme France; AVINZA↧—King Pharmaceuticals Research and Development, Inc.; AVONEX↧, TECFIDERA and TYSABRI↧—Biogen Idec MA, Inc.; BETASERON↧—Bayer Pharma AG; BYDUREON and BYETTA↧—Amylin Pharmaceuticals, LLC; CAMPRAL↧—Merck Sante; CARDIZEM↧—Valeant International Bermuda; COPAXONE↧—Teva Pharmaceutical Industries Ltd.; DILZEM↧—Cephalon (UK) Limited or Warner-Lambert Company LLC (depending on the jurisdiction); DILTELAN↧—Elan Corporation plc or Cephalon Limited (depending on the jurisdiction); EMEND↧—Merck Sharp & Dohme Corp.; EXTAVIA↧, FOCALIN XR↧, GILENYA and RITALIN LA↧—Novartis AG; INVEGA↧ SUSTENNA↧, RISPERDAL CONSTA and XEPLION↧—Johnson & Johnson Corp. (or its affiliate); LUVOX CR↧—Abbott Laboratories; MEGACE↧—E.R. Squibb & Sons, LLC; NAPRELAN↧— Alvogen Pharma US Inc.; RAPAMUNE↧—Wyeth LLC; REBIF↧—Ares Trading S.A.; SUBOXONE↧ and SUBUTEX↧—Reckitt Benckiser Healthcare (UK) Ltd.; SUPRALIP and TRICOR↧—Fournier Industrie et Sante Corporation; UNIVER↧—various non-Alkermes entities (depending on the jurisdiction); VICTOZA↧—Novo Nordisk A/S LLC; ZOHYDRO↩—Zogenix, Inc.; and ZYPREXA↧ and ZYPREXA RELPREVV↧—Eli Lilly and Company. Other trademarks, trade names and service marks appearing in this Directors’ Report are the property of their respective owners. Principal Activities Alkermes plc (as used in this section, together with our subsidiaries, ‘‘us’’, ‘‘we’’, ‘‘our’’, or the ‘‘Company’’) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on our own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a diversified portfolio of more than 20 commercial drug products and a 2 clinical pipeline of product candidates that address central nervous system (‘‘CNS’’) disorders such as addiction, schizophrenia and depression. On September 16, 2011, the business of Alkermes, Inc. and the drug technologies business (‘‘EDT’’) of Elan Corporation, plc (‘‘Elan’’) were combined under Alkermes plc (this combination is referred to as the ‘‘Business Combination,’’ the ‘‘acquisition of EDT’’ or the ‘‘EDT acquisition’’). Our ordinary shares are listed on the NASDAQ Global Select Market, where our trading symbol is ‘‘ALKS.’’ Our principal offices are located at Connaught House, 1 Burlington Road, Dublin 4, Ireland. We have a research and development (‘‘R&D’’) center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. Business Overview Marketed Products We earn manufacturing and/or royalty revenues on net sales of products marketed by our partners and earn revenue on net sales of VIVITROL, which is a proprietary product that we manufacture, market and sell in the U.S. Our marketed products are described in the table below, including, among other things, the territory in which the marketer has the right to sell the product and the source of revenues for us: Product Indication(s) Technology Territory Revenue Source Marketer RISPERDAL Schizophrenia Extended-release Worldwide Manufacturing and Ortho-McNeil-Janssen CONSTA Bipolar I Disorder microsphere Royalty Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (taken together, ‘‘Janssen’’) INVEGA Schizophrenia NanoCrystal United States Royalty Janssen SUSTENNA/ (U.S.) XEPLION Rest of World (‘‘ROW’’) AMPYRA/ Treatment to Oral Controlled U.S. Manufacturing and Acorda FAMPYRA improve walking Release (‘‘OCR’’) ROW Royalty Therapeutics, Inc. in patients with Matrix Drug (‘‘Acorda’’) multiple Absorption System Biogen Idec sclerosis (‘‘MS’’), (MXDAS) International GmbH as (‘‘Biogen Idec’’), under demonstrated by sublicense from Acorda an increase in walking speed BYDUREON Type 2 diabetes Extended-release Worldwide Royalty AstraZeneca plc microsphere (‘‘AstraZeneca’’) VIVITROL Alcohol Extended-release U.S. Product sales Alkermes dependence microsphere Russia and Manufacturing and Cilag GmbH Opioid dependence Commonwealth of Royalty International (‘‘Cilag’’) Independent States (‘‘CIS’’) TRICOR Cholesterol NanoCrystal Worldwide Royalty AbbVie Inc. LIPANTHYL lowering Abbott Laboratories LIPIDIL SUPRALIP (and other trade names under which fenofibrate 48 mg and 145 mg are sold) 3 Product Indication(s) Technology Territory Revenue Source Marketer ZANAFLEX Muscle spasticity OCR U.S. Manufacturing Acorda; Actavis, Inc. CAPSULES Spheroidal Oral (capsules only) and (formerly Watson ZANAFLEX Drug Absorption Royalty Pharmaceutical) TABLETS System (SODAS) TIZANIDINE HYDROCHLORIDE (AB Rated to ZANAFLEX CAPSULES) AVINZA Chronic moderate OCR U.S. Manufacturing and Pfizer Inc. (‘‘Pfizer’’) to severe pain (SODAS) Royalty EMEND Nausea associated NanoCrystal Worldwide Manufacturing and Merck & Co. Inc. with Royalty (‘‘Merck’’) chemotherapy and surgery FOCALIN XR Attention Deficit OCR Worldwide Manufacturing and Novartis AG RITALIN LA Hyperactivity (SODAS) Royalty (‘‘Novartis’’) Disorder MEGACE ES Anorexia, Cachexia NanoCrystal U.S. Royalty Strativa associated Pharmaceuticals with AIDS (a business division of Par Pharmaceutical Companies, Inc.) LUVOX CR Obsessive- OCR U.S. Royalty Jazz compulsive (SODAS) Pharmaceuticals plc disorder (‘‘Jazz’’) RAPAMUNE Prevention of renal NanoCrystal Worldwide Manufacturing Pfizer transplant rejection NAPRELAN Various mild to OCR U.S. Manufacturing Shionogi moderate Intestinal Canada pain indications Protective Drug Absorption System (IPDAS) VERAPAMIL SR Hypertension OCR Licensed on Manufacturing and Kremers-Urban; VERELAN (SODAS) country/region Royalty (on select Cephalon; VERELAN PM basis throughout formulations) Aspen Pharma; VERAPAMIL PM the world Actavis, Inc. VERACAPS UNIVER DILZEM SR Hypertension OCR Licensed on Manufacturing and Cephalon; DILZEM XL and/or Angina (SODAS) country/region Royalty (for Kun-Wha DILTELAN basis throughout CARDIZEM Pharmaceutical Co. Ltd; CARDIZEM CD the world CD only) Sanofi; Valeant Pharmaceuticals International Inc. AFEDlTAB CR Hypertension OCR U.S. Manufacturing Actavis, Inc. (AB Rated (MXDAS) to ADALAT CC) ZOHYDRO ER Severe pain OCR U.S. Manufacturing and Zogenix, Inc. (SODAS) royalty Our key marketed products are expected to generate significant revenues for us in the near- and medium-term. They possess long patent lives, and we believe are singular or competitively advantaged
Recommended publications
  • Alkermes Public Limited Company
    ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Year Ended March 31, 2013 ALKERMES PLC Table of Contents Page Directors’ Report .......................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ........................................... 59 Consolidated Statement of Comprehensive Income (Loss) ............................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 63 Consolidated Reconciliation of Shareholders’ Funds ................................. 62 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 111 Company Balance Sheet ..................................................... 113 Notes to the Company Financial Statements ....................................... 114 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the fiscal year ended March 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2009, which provides that a true and fair view of the state of
    [Show full text]
  • In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated
    Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 1 of 49 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS In re ALKERMES SECURITIES ) Master Docket No. 03-CV-12091-RCL LITIGATION ) ) CLASS ACTION This Document Relates To: ) ) ALL ACTIONS. ) ) ) CONSOLIDATED COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 2 of 49 SUMMARY AND OVERVIEW 1. This is a securities class action on behalf of all purchasers of the common stock of Alkermes, Inc. (“Alkermes” or the “Company”) between April 22, 1999 and July 1, 2002 (the “Class Period”), against Alkermes and certain of its officers and directors for violations of the Securities Exchange Act of 1934 (the “Exchange Act”). 2. Alkermes is a biopharmaceutical company focused on the development of controlled- release drug delivery technologies and their application to existing or new drug therapies. Among the drug delivery technologies defendants seek to develop are sustained-release systems based on biodegradable polymeric microspheres, including those based on Medisorb polymers. 3. In 1996, Alkermes entered into an agreement with JPI Pharmaceutical International (“Janssen”), an affiliate of pharmaceutical giant Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“Johnson & Johnson”), to develop an injectable form of the schizophrenic drug Risperdal, based upon the Medisorb polymer technology, called Risperdal Consta. Janssen has marketed the oral form of Risperdal since 1993, with sales of $2.3 billion in 2003. According to a December 12, 2001 report by analysts Thomas Weisel Partners, LLC (“Thomas Weisel”), during the Class Period, oral Risperdal was the most prescribed drug in the $5.3 billion atypical antipsychotic market.
    [Show full text]
  • Explanation of Conflict of Interest Disclosure Parts: Part One: All
    Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present) Part Two: Income Sources & Equity of $10,000 or greater Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present): Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present) Part Five: My primary employer is a pharmaceutical/biotech/medical device company. 2012 Program Committee Disclosures Anissa Abi-Dargham: Part 1: Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; Part 2: Pierre Favre William Carlezon: Part 1: Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; Part 2: (Spouse) Senior Scientist, EMD Serono, Part 3: (Spouse) Senior Scientist, EMD Serono Cameron Carter: Part1: GlaxoSmithKline research; Part 4: GlaxoSmithKline Karl Deisseroth: Part
    [Show full text]
  • Corporate Responsibility Report
    Corporate Responsibility Report October 2019 ©2019 Alkermes. All rights reserved. Table of Contents Section 1: Introduction . 2 Section 2: About Our Company . 3 Section 3: Our Approach to Corporate Responsibility . 4 Section 4: Environment . 6 Section 5: Social . 15 Section 6: Governance . 23 Section 7: The Future of Corporate Responsibility at Alkermes and About This Report . 27 ALKERMES • CORPORATE RESPONSIBILITY REPORT 1 SECTION 1 INTRODUCTION A Message from Our CEO Alkermes was founded by pioneers in the field of Inspired by the courage and determination of individuals neuroscience, and their legacy of innovation and in these frequently underserved and marginalized scientific excellence — applied to the real-world needs communities, we are driven to develop medicines and of patients — remains central to our mission. Alkermes contribute to systemic solutions that we hope will have technologies and discoveries have contributed to a meaningful impact on the lives of patients. important medicines that continue to shape the treatment landscape in many disease areas. Today, Our Commitment we are distinguished from other biopharmaceutical As we look toward building our business for the companies by our core focus on serious mental illness future, we are guided by the opportunity — and what and addiction — chronic, highly prevalent conditions we believe is our responsibility — to help address the that affect millions of people and represent some of unmet needs of patients and to operate in a sustainable, the most challenging public health issues of our time. socially responsible manner. We firmly believe that doing so is best for our business, our employees, for Great science. Deep compassion.
    [Show full text]
  • Numeric Listing of Manufacturers That Have Signed Rebate Agreements
    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements January 1, 2020 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00172 IVAX PHARMACEUTICALS, INC. 1/1/1991 Y 00003 E.R. SQUIBB & SONS, LLC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 00004 HOFFMANN-LA ROCHE 1/1/1991 00178 MISSION PHARMACAL COMPANY 1/1/1991 00006 MERCK & CO., INC. 1/1/1991 Y 00182 GOLDLINE LABORATORIES, INC. 1/1/1991 00007 GLAXOSMITHKLINE 1/1/1991 00185 EON LABS, INC. 1/1/1991 Y 00008 WYETH LABORATORIES 1/1/1991 Y 00186 ASTRAZENECA PHARMACEUTICAL 1/1/1991 Y 00009 PHARMACIA AND UPJOHN COMPA 1/1/1991 Y 00187 BAUSCH HEALTH US, LLC. 1/1/1991 Y 00013 PHARMACIA AND UPJOHN COMPA 1/1/1991 Y 00206 WYETH PHARMACEUTICALS LLC 1/1/1991 Y 00015 MEAD JOHNSON AND COMPANY 1/1/1991 Y 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00023 ALLERGAN INC 1/1/1991 00225 B. F. ASCHER AND COMPANY, INC. 1/1/1991 00024 SANOFI-AVENTIS, US LLC 1/1/1991 Y 00228 ACTAVIS ELIZABETH LLC 1/1/1991 Y 00025 GD. SEARLE LLC DIVISION OF PFIZ 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES, I 1/1/1991 Y 00026 BAYER HEALTHCARE LLC 1/1/1991 Y 00254 PAR PHARMACEUTTICAL INC. 9/28/2018 00029 GLAXOSMITHKLINE 1/1/1991 00258 FOREST LABORATORIES INC 1/1/1991 00032 ABBVIE INC. 1/1/1991 Y 00259 MERZ PHARMACEUTICALS 1/1/1991 00037 MEDA PHARMACEUTICALS, INC.
    [Show full text]
  • Obesity, Diabetes, & Diet
    Obesity, Diabetes, & Diet COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE Case Study Louis J. Aronne, MD, FACP Weill Cornell Medical College Columbia University College of Physicians and Surgeons Louis J. Aronne, MD, FACP Disclosures !! Research/Grants: Amylin Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc.; F. Hoffmann-La Roche, Ltd.; Metabolous Pharmaceuticals, Inc.; Norvo Nordisk; Orexigen Therapeutics, Inc.; Pfizer Inc.; TransTech Pharma, Inc. !! Speakers Bureau: None !! Consultant: Allergan, Inc.; Amylin Pharmaceuticals, Inc.; GI Dynamics, Inc.; GlaxoSmithKline Consumer Healthcare, LP; Johnson & Johnson Pharmaceutical Research & Development, LLC; NeuroSearch, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche Laboratories, Inc.; VIVUS, Inc.; Wyeth Pharmaceuticals, Inc. !! Stockholder: Cardiometabolic Support Network, LLC !! Other Financial Interest: None !! Advisory Board: Allergan, Inc.; Amylin Pharmaceuticals, Inc.; GI Dynamics, Inc.; GlaxoSmithKline Consumer Healthcare, LP; Johnson & Johnson Pharmaceutical Research & Development, LLC; NeuroSearch, Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche Laboratories, Inc.; VIVUS, Inc.; Wyeth Pharmaceuticals, Inc. Father A.V. 04May09: 378 lbs, 5’ 11”, BMI = 53 !! Dx w/ DMII in 2004 !! Long history of obesity !! Can’t control his eating, binges !! HbA1c = 8.4% !! FPG = 166 !! TG = 241 !! UA Microalbumin = 973 !! “Can’t tolerate metformin” !! Considering RYGB, but afraid to have surgery DMII = diabetes mellitus type II; Hb = hemoglobin; FPG = fasting plasma glucose;
    [Show full text]
  • Commercial Products
    Website www.alkermes.com Ticker Symbol (NASDAQ) ALKS Alkermes, Inc. is a fully integrated biotechnology company that develops medicines designed to yield better outcomes Contacts and improve patients’ lives. Our products, which use novel molecules and innovative drug technologies, target Rebecca Peterson Vice President, Corporate widespread diseases including central nervous system (CNS) disorders, addiction and diabetes. We approach the drug Communications development process from a patient-centric perspective, beginning with a thorough understanding of the challenges Voice: 617-583-6378 patients face on a day-to-day basis. Our products are designed with patient needs and behaviors in mind, with the goal Blair Jackson of ensuring that patients consistently take their medication for long-term treatment success. Vice President, Business Development Alkermes has multiple partnered programs and also works independently to develop and commercialize proprietary Voice: 617-250-1594 products. The company has built a wide range of capabilities, including innovative research programs, clinical development, large-scale manufacturing, and a commercial presence in the marketplace. Corporate Headquarters Alkermes, Inc. 88 Sidney Street Cambridge, MA 02139 VIVITROL® Voice: 617-494-0171 Commercial Products (naltrexone for extended-release injectable suspension) Fax: 617-494-9263 RISPERDAL® CONSTA® [(risperidone) long-acting injection] Product: VIVITROL is an injectable formulation of naltrexone, based on Alkermes’ unique Medisorb Product: RISPERDAL CONSTA is a long-acting injectable technology. VIVITROL is designed for once-monthly form of Johnson & Johnson’s schizophrenia drug, dosing, eliminating the need for patients to make a RISPERDAL. Developed utilizing Alkermes’ proprietary daily decision about taking their medicine. Alkermes Medisorb® technology, RISPERDAL CONSTA is manufactures VIVITROL at its commercial facility in Ohio administered once every two weeks, rather than daily, and markets the product independently in the U.S.
    [Show full text]
  • In Re Incretin-Based Therapies Products Liability Litigation Transfer Order
    Case MDL No. 2452 Document 71 Filed 08/26/13 Page 1 of 4 UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION MDL No. 2452 TRANSFER ORDER Before the Panel: Pursuant to 28 U.S.C. § 1407, plaintiffs in two Southern District of California actions move to centralize this litigation, which involves four anti-diabetic medications that plaintiffs contend cause pancreatic cancer, in the Southern District of California. This litigation currently consists of 53 actions pending in seven districts, as listed on Schedule A.1 All responding parties support centralization. Plaintiffs in fifteen Southern District of California actions and a District of Arizona action support plaintiffs’ motion in its entirety. Defendants2 support centralization in the Southern District of California or, alternatively, the District of Colorado or the Western District of Oklahoma. On the basis of the papers filed and hearing session held, we find that these actions involve common questions of fact, and that centralization of all actions in the Southern District of California will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. Plaintiffs in all actions allege that the use of one or more of four anti-diabetic incretin- based medications – Janumet (sitagliptin combined with metformin), Januvia (sitagliptin), Byetta (exenatide) and Victoza (liraglutide) – caused them or their decedent to develop pancreatic cancer. Centralization will eliminate duplicative discovery; prevent inconsistent pretrial rulings (particularly on such matters as Daubert rulings); and conserve the resources of the parties, their counsel, and the judiciary. We are “typically hesitant to centralize litigation against multiple, competing defendants which marketed, manufactured and sold similar products.” In re Yellow Brass Plumbing Component Prods.
    [Show full text]
  • Curriculum Vitae
    David C. Klonoff MD, FACP, FRCP (Edin), Fellow AIMBE Page 1 CURRICULUM VITAE DAVID CHARLES KLONOFF, M.D., FACP, FRCP (Edin), FELLOW AIMBE Medical Director, Diabetes Research Institute, Mills-Peninsula Medical Center 100 South San Mateo Drive, Room 5147, San Mateo, California 94401 Phone 650-696-4260 / Fax 650-696-4269 dklonoff@diabetestechnology.org SUMMARY David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor- in-Chief of Journal of Diabetes Science and Technology. He has authored over 270 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity.
    [Show full text]
  • Signatory Companies
    PhRMA Direct to Consumer Advertising Principles Signatory Companies In October 2018, the PhRMA BoArd of Directors Adopted meAsures to enhAnce the PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription Medicines. The revised, voluntAry Principles become effective on April 15, 2019. The revised, voluntAry Principles include A new guiding principle stAting thAt “[A]ll DTC television Advertising thAt identifies A prescription medicine by nAme should include direction as to where patients can find information about the cost of the medicine, such as a company- developed website, including the list price And Average, estimAted or typicAl pAtient out-of- pockets costs, or other context About the potentiAl cost of the medicine.” The Principles Also stAte thAt PhRMA will identify on its website All compAnies thAt voluntArily And independently commit to Abide by the Principles And will identify compAnies thAt complete, At the AppropriAte time, AnnuAl certificAtions thAt they hAve policies And procedures in plAce to foster compliAnce with the Principles. The following is A list of All signAtory compAnies who hAve Announced thAt they intend to Abide by the Principles: AbbVie GlAxoSmithKline Alexion Pharmaceuticals, Inc. Incyte CorporAtion Alkermes plc. Ipsen BiophArmAceuticAls, Inc. Allergan plc Johnson & Johnson Amgen Inc. Lundbeck Inc. Astellas Americas Merck & Co., Inc. AstrAZenecA PhArmAceuticAls LP NovArtis PhArmAceuticAls CorporAtion Bayer CorporAtion Novo Nordisk Inc. Biogen OtsukA AmericA PhArmAceuticAl, Inc. (OAPI) BioMArin PhArmAceuticAl Inc. Pfizer Inc Boehringer Ingelheim PharmAceuticAls, Inc. Purdue PhArmA L.P. Bristol-Myers Squibb CompAny Sanofi Celgene CorporAtion Sunovion Pharmaceuticals Inc. Daiichi SAnkyo, Inc. TakedA PhArmAceuticAls USA, Inc. EisAi Inc. TevA PhArmAceuticAls Eli Lilly And CompAny UCB EMD Serono .
    [Show full text]
  • Schedule 14A Schedule 14A Information
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: ☑ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a- 6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § Rule 14a-12 ALKERMES PLC (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☑ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: NOT APPLICABLE (2) Aggregate number of securities to which transaction applies: NOT APPLICABLE (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): NOT APPLICABLE (4) Proposed maximum aggregate value of transaction: NOT APPLICABLE (5) Total fee paid: NOT APPLICABLE o Fee paid previously with preliminary materials: NOT APPLICABLE o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]